FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Emry Kent		 2. Issuer Name and Ticker or Trading Symbol

BioCorRx Inc. [ BICX ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

2390 EAST ORANGEWOOD AVENUE, SUITE 500		 3. Date of Earliest Transaction (MM/DD/YYYY)

6/30/2022
(Street)

ANAHEIM, CA 92806
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.001 6/30/2022  A(1)  2092 A$0.00 97723 D  
Common Stock, par value $0.001 9/30/2022  A(2)  2450 A$0.00 100173 D  
Common Stock, par value $0.001 12/30/2022  A(3)  5319 A$0.00 105492 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
(1) These shares were issued to Mr. Emry pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Emry. As compensation for his services, Mr. Emry shall be issued, upon the last day of each fiscal quarter, provided Mr. Emry is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.39.
(2) These shares were issued to Mr. Emry pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Emry. As compensation for his services, Mr. Emry shall be issued, upon the last day of each fiscal quarter, provided Mr. Emry is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.04.
(3) These shares were issued to Mr. Emry pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Emry. As compensation for his services, Mr. Emry shall be issued, upon the last day of each fiscal quarter, provided Mr. Emry is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.94.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Emry Kent
2390 EAST ORANGEWOOD AVENUE
SUITE 500
ANAHEIM, CA 92806		X
Signatures
/s/ Kent Emry1/6/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
BioCorRx (QB) (USOTC:BICX)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more BioCorRx (QB) Charts.
BioCorRx (QB) (USOTC:BICX)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more BioCorRx (QB) Charts.